Newleos Begins UK Trial of Anxiety Disorder Drug NTX-1955

Biotechnology company doses first participant in Phase 1b study of novel treatment for generalized anxiety.

Apr. 1, 2026 at 3:24pm

Got story updates? Submit your updates here. ›

Newleos Therapeutics, a clinical-stage biotechnology company, has announced that the first participant has been dosed in the company's third Phase 1b study of its investigational drug NTX-1955. The study is designed to evaluate the safety and efficacy of NTX-1955 in treating generalized anxiety disorder.

Why it matters

Generalized anxiety disorder is one of the most undertreated mental health conditions, and current pharmacological options have significant limitations. The development of new, innovative treatments like NTX-1955 could provide much-needed relief for those suffering from debilitating anxiety.

The details

The Phase 1b study will be conducted in the United Kingdom and is the third trial of NTX-1955 for generalized anxiety disorder. Newleos is a clinical-stage biotechnology company focused on developing new treatments for neuropsychiatric disorders.

  • The first participant was dosed on April 1, 2026.

The players

Newleos Therapeutics, Inc.

A clinical-stage biotechnology company developing innovative treatments for neuropsychiatric disorders.

NTX-1955

An investigational drug being studied by Newleos for the treatment of generalized anxiety disorder.

Got photos? Submit your photos here. ›

The takeaway

The initiation of this Phase 1b trial for NTX-1955 represents an important step forward in the development of new treatment options for the millions of people suffering from generalized anxiety disorder, a condition that often goes undertreated due to the limitations of existing medications.